COMP and rheumatoid arthritis: Hence, the aim of this study was to evaluate how a potential novel prognostic marker such as COMP, as well as disease activity measures, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), RA associated auto-antibodies, traditional CVD risk factors, and time to disease-modifying anti-rheumatic drugs (DMARD) treatment and inflammation control over time predict future CVD in patients with early RA.